RESULTS OF OPERATIONS AND FINANCIAL CONDITION On August 6, 2026, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously reported, on June 30, 2026, Nuvation Bio Inc. (the “Company”) completed its registered underwritten public offering (the “Offering”) of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032 (the “Notes”), pursuant to the Underwriting Agreement, dated June 25, 2026 (the “Underwriting Agreement”) with Jefferies LLC, Citigroup Global Mark…

of the Company’s Current Report on Form 8-K filed with the SEC on June 30, 2026 (the “Prior 8-K”), which descriptions are incorporated herein by reference. The description of the Indenture and of the Notes included herein and in the Prior 8-K do not purport to be complete and are qualified in their entirety by reference to the complete text of the Base Indenture and the Supplemental Indenture and the form of note attached thereto, which were filed as exhibits to the Prior 8-K and are incorpor…

Termination of a Material Definitive Agreement. The information set forth under

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under

of this Current Report on Form 8-K is incorporated herein by reference. In connection with the Offering and the issuance of Notes thereunder, on June 30, 2026, the Company completed a voluntary prepayment of all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to approximately $58.5 million in the aggregate (the “Payoff Amount”), under the Loan Agreement. Upon receipt by the Agent of the Payoff Amount on June 30, 2026, all obligations, covenants, debts and l…

below. Pursuant to the terms of the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to an additional $37.5 million aggregate principal amount of the Notes. The Notes were offered and sold in a public offering registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to a registration statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2025, which automatically became effectiv…

RESULTS OF OPERATIONS AND FINANCIAL CONDITION On May 4, 2026, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Ex…

RESULTS OF OPERATIONS AND FINANCIAL CONDITION On March 2, 2026, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under t…

Results of Operations and Financial Condition. On January 12, 2026, the Company issued a press release announcing, among other things, the Company’s preliminary unaudited cash, cash equivalents and marketable securities for the fiscal year ended December 31, 2025 and preliminary net product revenue of IBTROZI. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Entry into a Material Definitive Agreement. On January 11, 2026, Nuvation Bio Inc. (the “Company”) entered into a License and Collaboration Agreement (the “License Agreement”) with Eisai Co., Ltd. (“Eisai”). Pursuant to the License Agreement, the Company granted Eisai an exclusive license to develop and commercialize licensed products containing taletrectinib in the following territories: the European Union and all member states thereof, Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia…

RESULTS OF OPERATIONS AND FINANCIAL CONDITION On November 3, 2025, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing und…

RESULTS OF OPERATIONS AND FINANCIAL CONDITION On August 7, 2025, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the…

Other Events. On June 11, 2025, Nuvation Bio Inc. (the “Company”) announced that the U.S. Food and Drug Administration has approved IBTROZI TM (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The FDA approval of IBTROZI is supported by one of the largest global clinical trial programs in ROS1+ NSCLC to date, with over 300 patients enrolled in the pivotal TRUST-I and TRUST-II studies. In TRUST-I, IBTROZI achieved…

RESULTS OF OPERATIONS AND FINANCIAL CONDITION On May 7, 2025, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Ex…

Entry into a Material Definitive Agreement. On March 21, 2025, Nuvation Bio Inc. (the “Company”) entered into a commercial supply agreement (the “Supply Agreement”) with Asymchem Life Science (Tianjin) Co., Ltd. (“Asymchem”) to supply the Company with taletrectinib drug product (the “Products”). Asymchem will be a non-exclusive supplier of the Products to the Company, and the Company will retain the right to procure the Products from one or more alternate and/or backup manufacturers of the Pr…

RESULTS OF OPERATIONS AND FINANCIAL CONDITION On March 6, 2025, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under t…

Entry into a Material Definitive Agreement. On March 3, 2025, Nuvation Bio Inc. (the “Company”) entered into a commercial supply agreement (the “Supply Agreement”) with Asymchem Laboratories (Tianjin) Co., Ltd. (“Asymchem”) to supply the Company with taletrectinib drug substance (the “Products”). Asymchem will be a non-exclusive supplier of the Products to the Company, and the Company will retain the right to procure the Products from one or more alternate and/or backup manufacturers of the P…

Entry into a Material Definitive Agreement. Loan Agreement On March 3, 2025 (the “Closing Date”), Nuvation Bio Inc. (the “Company”) entered into a $100.0 million senior secured loan agreement (the “Loan Agreement”), with Sagard Holdings Manager LP (“Sagard”) as administrative agent, and the lenders party thereto. An initial tranche of $50 million will be funded upon FDA Approval (as defined in the Loan Agreement) of taletrectinib on or prior to September 30, 2025. The second tranche of $50 mi…

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NUVATION BIO INC. Date: March 4, 2025 By: /s/ Moses Makunje Name: Moses Makunje Title: Principal Accounting Officer

Chief Executive Officer of AnHeart Therapeutics and Director — Dr. Jerry Wang: Dr. Jerry Wang departed following the achievement of key company goals and successful integration.

RESULTS OF OPERATIONS AND FINANCIAL CONDITION On November 6, 2024, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing und…

RESULTS OF OPERATIONS AND FINANCIAL CONDITION On August 5, 2024, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the…

Other Events. The description of the Company’s business set forth in Item 1 of its Annual Report on Form 10-K filed on Feb ruar y 29, 2024 (the “Form 10-K”) does not reflect the completion of the acquisition of AnHeart on April 9, 2024. The following description of the Company’s business has been updated to reflect the completion of this acquisition and supersedes in its entirety Item 1 set forth in the Form 10-K. The Company’s risk factor disclosure set forth in its Quarterly Report on Form…

RESULTS OF OPERATIONS AND FINANCIAL CONDITION On May 14, 2024, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information contained in this Form 8-K, including in the accompanying Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the E…